Bharangin, A Diterpenoid, Enhances the Sensitivity of Pancreatic Cancer Cells to Gemcitabine Through Involvement of Long Non-Coding RNAs and Nuclear Factor-κB.

Pancreatic cancer (PaCa) manifests as an aggressive tumour due to the late occurrence of early symptoms. The overall 5-year survival rate of PaCa is merely 2%-9%. Bharangin (BG), a diterpenoid quinonemethide known for its anti-cancer activities, was…

Preview only. Read the full abstract at the source